Trade Unlisted is not regulated by the Securities and Exchange Board of India (SEBI). Investments in unlisted securities involve significant risk, including the risk of complete loss of capital. The filing of a Draft Red Herring Prospectus (DRHP) does not guarantee that an Initial Public Offering (IPO) will occur. Unlisted securities are inherently illiquid, price discovery may be limited, and exit opportunities may not materialize.
Trade Unlisted provides news, insights, and general market information for informational and educational purposes only. The content should not be construed as financial, investment, legal, or tax advice. Trade Unlisted does not act as a broker, investment advisor, fiduciary, or intermediary, and does not endorse, recommend, solicit, or validate any investment opportunity. Users are solely responsible for conducting their own independent due diligence before making any financial or investment decisions.
All information is derived from publicly available sources and market observations. While reasonable care is taken in preparing content, Trade Unlisted makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of the information provided. Users should independently verify all information prior to relying on it.
Lord’s Mark Industries Achieves Global Breakthrough in HIV Diagnostics, Enters Exclusive Group of Nine Worldwide
Lord’s Mark Industries Achieves Global Breakthrough in HIV Diagnostics, Enters Exclusive Group of Nine Worldwide
- The company has received approval from the Central Licensing Authority to manufacture its LordsMed HIV 1 & 2 Self-Test, a high-risk Class D in-vitro diagnostic device.
- With this approval, it becomes:
- Among only 3 approved companies in India
- One of 9 companies globally to achieve this milestone
- The approval is specifically for export markets, not for domestic commercial sale in India.
- Exports are expected to begin from June 2026, targeting:
- Africa
- Europe
- Latin America
- The product is a self-use rapid diagnostic test that:
- Detects HIV-1 and HIV-2 antibodies
- Uses a simple finger-prick blood sample
- Does not require laboratory infrastructure
- It is based on lateral flow immunoassay technology, widely used in rapid diagnostic kits.
- The global HIV self-testing market is expected to see strong growth, driven by:
- Rising awareness
- Policy support
- Demand for private, accessible testing solutions
- Key demand regions:
- Africa: Highest HIV burden and large-scale public health programs
- Europe: Increasing consumer-led and privacy-driven testing
- Latin America: Growing adoption supported by government initiatives
- The milestone strengthens India’s position as a global hub for regulated medical diagnostics manufacturing.
- The development is led by LordsMed, the healthcare division of the company, which focuses on diagnostics, medical devices, and rapid testing solutions.
- The company aims to expand access to reliable, private, and early HIV detection globally, improving health outcomes.
Comments